Jarema Marek, Meder Joanna, Araszkiewicz Aleksander, Tyszkowska Magdalena
III Klinika Psychiatryczna IPiN w Warszawie.
Psychiatr Pol. 2008 Nov-Dec;42(6):841-58.
The aim was to obtain the information regarding the choice of antipsychotic drugs in the treatment of first episode schizophrenia. In particular, the factors influencing doctors' preferences and their opinion about several antipsychotics and the availability of these drugs were evaluated.
The anonymous questionnaire was presented to 100 psychiatrists; 50 of them were in hospital and 50 were in the out-patient practice. The questionnaire consisted of 17 questions regarding the pharmacological treatment of the first schizophrenic episode.
The most frequently prescribed drug was olanzapine (33%), then risperidone (26%), and perazine (25%). In hospitals, risperidone was more frequently administered than perazine (29% and 24% respectively) while in out-patient clinics perazine slightly outnumbered risperidone (25% vs 23%). Fluoxetine was prescribed to 18% of out-patients, but not to hospitalized ones. Doctors performed treatment verification mainly (in 39% of patients) after 4 weeks of therapy. The change of antipsychotics was made more frequently in 28% of those hospitalized than the out-patients (16%) and mainly due to the lack of efficacy. More psychiatrists considered the most important attribute of the drug to be the efficacy toward the negative symptoms (77%) than the positive symptoms (59% of doctors).
Prescription practice of psychiatrists shows the popularity of olanzapine and risperidone in the treatment of the first psychotic episode, but also indicates the strong position of perazine, which results from the current administrative regulations. Three times more psychiatrists think that patients should have an unrestricted (by the law) access to olanzapine or risperidone than to perazine. The most important attribute of an antipsychotic in the first episode schizophrenia turned out to be its efficacy toward the negative symptoms. Psychiatrists admitted that they chose an antipsychotic much more frequently on the basis of their own knowledge than on the basis of experts' opinion or the administrative regulations.
旨在获取有关抗精神病药物在初发精神分裂症治疗中选择的信息。特别评估了影响医生偏好的因素、他们对几种抗精神病药物的看法以及这些药物的可获得性。
向100名精神科医生发放匿名问卷;其中50名在医院工作,50名在门诊执业。问卷包含17个关于首次精神分裂症发作药物治疗的问题。
最常处方的药物是奥氮平(33%),其次是利培酮(26%)和奋乃静(25%)。在医院,利培酮的使用频率高于奋乃静(分别为29%和24%),而在门诊诊所,奋乃静的使用人数略多于利培酮(25%对23%)。18%的门诊患者使用了氟西汀,但住院患者未使用。医生主要在治疗4周后(39%的患者)进行治疗核查。住院患者中28%更换抗精神病药物的频率高于门诊患者(16%),主要原因是缺乏疗效。更多精神科医生认为药物对阴性症状的疗效(77%)比阳性症状的疗效(59%的医生)更重要。
精神科医生的处方实践表明奥氮平和利培酮在首次精神病发作治疗中很受欢迎,但也表明了奋乃静的重要地位,这是由现行行政法规导致的。认为患者应不受法律限制使用奥氮平或利培酮的精神科医生是认为患者应不受法律限制使用奋乃静的医生的三倍。在首次发作精神分裂症中,抗精神病药物最重要的属性是其对阴性症状的疗效。精神科医生承认,他们选择抗精神病药物更多是基于自己的知识,而非专家意见或行政法规。